Galena Biopharma Issued Folate Binding Protein Cancer Vaccine Patent in Japan
Galena Biopharma (NASDAQ: GALE), a biotechnology company focused on developing innovative, targeted oncology treatments, today announced the issuance of a patent from the Japan Patent Office for a Composition of Matter and Method of Treatment patent covering Folate Binding Protein (FBP) peptide variants for use either alone or in combination with the FBP cancer vaccine, E39. The Japanese patent provides exclusivity in the country until 2022, with additional worldwide patent filings pending.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.